Neuroendocrine Responses to High-Intensity Reactive Exercises: Effects on Catecholamine and Hormonal Profiles in Elite U-19 Volleyball Players

November 14, 2026 updated by: Youssef Zekailiche, Mohamed Lamine Debaghine Setif 2 University

Acute Catecholamine and Glucocorticoid Responses to Reactive Speed, Agility, and Quickness Exercise in Elite U-19 Volleyball Players: A Randomized Controlled Study

The goal of this explored study intends to investigate how different types of speed, agility, and quickness (SAQ) exercises effect the body's immediate hormonal and physiological reactions in young male volleyball players. Physical exercise can alter the release of hormones and other substances involved in the body's response to physical effort and stress. However, it is still ambiguous if activities that necessitate swift reflexes to unforeseen visual stimuli provide distinct outcomes in contrast to conventional exercises that entail premeditated movements. The study will include 36 competitive male volleyball players under 19 years of age from the Algerian Amateur League. Participants will be randomly assigned to one of three groups, with 12 players in each group. The first group will conduct a 10-minute reactive training session using BlazePod, an interactive lighting system that requires participants to respond swiftly to visual inputs. The second cohort will engage in a 20-minute session with the identical approach, featuring increased workout repetitions and varied rest intervals. The third group will do 10 minutes of standard volleyball-related workouts without interactive visual indications. All participants will complete one supervised workout session. Blood samples will be collected roughly five minutes before exercise and within two minutes after exercise to assess five substances: epinephrine (adrenaline), norepinephrine (noradrenaline), dopamine, cortisol, and cortisone. These chemicals are involved in the body's responses to physical exertion and stress. Heart rate will also be recorded, and participants will report how physically challenging they found the exercises using a simple grading scale. Investigators will analyse data collected prior to and following physical activity and assess if the variations differ among the three cohorts. The study intends to better understanding of how exercise duration, physical demands, and responsiveness to visual signals may influence acute hormonal responses in young volleyball players. The results could assist researchers and sports experts in comprehending the physical requirements of reactionary exercise and inform subsequent studies on athletic training. The study is not meant to assess if these activities increase long-term sports performance. No results are currently available, and it is not yet known whether one workout strategy will create distinct hormonal reactions from another.

Study Overview

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Sétif, Algeria
        • Mohamed Lamine Debaghine Setif 2 University.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

17 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Male volleyball players within the U-19 age category.
  • Active participation in organized competitive volleyball.
  • Sufficient physical capacity to complete the prescribed high-intensity exercise protocols.
  • Absence of musculoskeletal injury or medical conditions that could compromise safe participation.
  • Willingness to complete the experimental procedures, including pre- and post-exercise venous blood sampling.

Exclusion Criteria:

  • Current musculoskeletal injury or persistent pain affecting physical performance.
  • Diagnosed cardiovascular, metabolic, endocrine, or neurological disorders that could influence exercise tolerance or biochemical responses.
  • Use of medications or substances known to affect sympathetic nervous system activity, catecholamine secretion, or glucocorticoid regulation.
  • Inability to complete the assigned exercise protocol or blood sampling procedures.
  • Withdrawal of consent at any stage of the investigation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: High-Intensity Exercise Group

12 individuals are participating in high-intensity physical training as part of supervised sessions. Heart rate and perceived exertion levels will be monitored, and blood samples will be collected before and after the program.

12 participants will undergo a single high-intensity exercise session under the supervision of specialists. The session will include a warm-up phase, followed by continuous moderate-intensity exercise, and will conclude with a cool-down phase. Exercise intensity will be monitored by measuring heart rate and assessing the perceived level of exertion. Additionally, blood samples will be collected before and after the session to evaluate hormonal responses.

Experimental: Moderate-Intensity Exercise Group

12 individuals will participate in moderate-intensity physical training as part of supervised sessions. Heart rate and perceived exertion levels will be monitored, and blood samples will be collected before and after the program.

12 participants will undergo a single moderate-intensity exercise session under the supervision of specialists. The session will include a warm-up phase, followed by continuous moderate-intensity exercise, and will conclude with a cool-down phase. Exercise intensity will be monitored by measuring heart rate and assessing the perceived level of exertion. Additionally, blood samples will be collected before and after the session to evaluate hormonal responses.

No Intervention: Control Group

12 participants will not undergo any physical intervention; instead, they will continue with their usual daily activities. Blood samples will be collected at the same time points established for the exercise groups.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Plasma Epinephrine Level
Time Frame: Before and immediately after the single exercise session

Plasma epinephrine concentration measured by blood sample. Change from baseline (before exercise) to immediately after the single exercise session will be compared between the high-intensity, moderate-intensity, and control groups.

Before and immediately after the single exercise session
Change in Plasma Norepinephrine Level
Time Frame: Before and immediately after the single exercise session

Plasma norepinephrine concentration measured by blood sample. Change from baseline (before exercise) to immediately after the single exercise session will be compared between the high-intensity, moderate-intensity, and control groups.

Before and immediately after the single exercise session
Change in Plasma Dopamine Level
Time Frame: Before and immediately after the single exercise session

Plasma dopamine concentration measured by blood sample. Change from baseline (before exercise) to immediately after the single exercise session will be compared between the high-intensity, moderate-intensity, and control groups.

Before and immediately after the single exercise session
Change in Serum Cortisol Level
Time Frame: Before and immediately after the single exercise session

Serum cortisol concentration measured by blood sample. Change from baseline (before exercise) to immediately after the single exercise session will be compared between the high-intensity, moderate-intensity, and control groups.

Before and immediately after the single exercise session
Change in Serum Cortisone Level
Time Frame: Before and immediately after the single exercise session

Serum cortisone concentration measured by blood sample. Change from baseline (before exercise) to immediately after the single exercise session will be compared between the high-intensity, moderate-intensity, and control groups.

Before and immediately after the single exercise session

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peak Heart Rate During Exercise
Time Frame: During the exercise session

Peak heart rate (HRpeak) will be measured continuously during each exercise session using a heart rate monitor. HRpeak will then be compared across the three groups: the high-intensity exercise group, the moderate-intensity exercise group, and the control group.

During the exercise session
Rating of Perceived Exertion
Time Frame: During and immediately after the single exercise session

The Rate of Perceived Exertion (RPE) will be assessed using the Borg scale during and immediately after each exercise session. RPE values will then be compared across the three groups: the high-intensity exercise group, the moderate-intensity exercise group, and the control group.

During and immediately after the single exercise session

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: YOUSSEF ZEKAILICHE, Ph.D., Mohamed Lamine Debaghine Setif 2 University Laboratory Sciences of Physical Activities, Sports, and Public Health, Algeria.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 5, 2026

Primary Completion (Actual)

October 15, 2026

Study Completion (Estimated)

December 5, 2026

Study Registration Dates

First Submitted

November 14, 2026

First Submitted That Met QC Criteria

November 14, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 14, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared to protect participant confidentiality and privacy, as this is a small single-site. Only aggregated and anonymized results will be reported.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe